Precision BioSciences, Inc.
NASDAQ:DTILBiotechnology
+$0.11 today
- Market cap
- $198.34M
- Beta
- 1.28
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$3.47
Volume 0.37M
Average 0.31M
DTIL Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Precision BioSciences, Inc.NASDAQ: DTIL
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$4M, compared with $1.69M a year earlier. Trailing-twelve-month accounts receivables was -$5.47M.
Context
- Accounts receivables amounted to 0.7% of revenue in FY2025, down 14.5 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near -$4M or moves back toward the trailing-twelve-month quarterly average of -$1.37M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 229K USD
- Year-over-year change
- -97.8%
- 4-year CAGR
- -60.6%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 229K | -97.8% |
| FY2024 | 2024-12-31 | 10.42M | +5858.0% |
| FY2023 | 2023-12-31 | (181K) | +22.0% |
| FY2022 | 2022-12-31 | (232K) | -102.4% |
| FY2021 | 2021-12-31 | 9.51M | — |
Accounts Receivables vs competitors
How DTIL compares with its peers on the latest reported figures
- DTIL's LTM Mar 2026 accounts receivables of $5.47M is the largest of the 7 companies compared; the peer median is $0.
- Its year-over-year change of -147.5% is the lowest of 3, against a peer median of -61.3%.
- Accounts receivables amounts to 12.1% of revenue for DTIL, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.47M | -147.5% | — | 12.1% | |
| LTM Mar 2026 | $4.96M | -63.0% | -13.5% | 3.3% | |
| LTM Mar 2026 | $2.67M | -59.5% | — | 4.8% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| FY2025 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding DTIL) | $0 | -61.3% | -13.5% | 0.0% | |
Competitors are the stored peer set for DTIL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.6M) | (111.64M) | (61.32M) | 7.17M | (45.72M) |
| Depreciation & Amortization | 10.2M | 9M | 8.26M | 4.58M | 2.75M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.51M | 19.2M | 14.04M | 12.6M | 10.19M |
| Change in Working Capital | 19.58M | 24.11M | (41.49M) | (54M) | (24.71M) |
| Accounts Receivables | 9.51M | (232K) | (181K) | 10.42M | 229K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 867K | 153K | 1.51M | (2.1M) | (737K) |
| Other Working Capital | 9.21M | 24.19M | (42.81M) | (62.33M) | (24.2M) |
| Other Non-Cash Items | (26.55M) | 13.57M | (3.6M) | (28.79M) | (8.35M) |
| Operating Cash Flow | (10.85M) | (45.75M) | (84.11M) | (58.45M) | (65.84M) |
| Capital Expenditures | (5.8M) | (3.32M) | (2.28M) | (250K) | (85K) |
| Acquisitions (Net) | 0 | 0 | 8M | 60K | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (750K) | 0 | 107K | (25K) | (549K) |
| Investing Cash Flow | (5.8M) | (3.32M) | 5.83M | (215K) | (634K) |
| Debt Repayment | 2.47M | 19.81M | 0 | (37K) | 0 |
| Common Stock Issued | 60.48M | 74.35M | 4.99M | 50.24M | 95.16M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.57M | 835K | 401K | 249K | 0 |
| Financing Cash Flow | 70.52M | 94.99M | 5.39M | 50.45M | 95.16M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 53.87M | 45.91M | (72.9M) | (8.21M) | 28.69M |
| Free Cash Flow | (16.66M) | (49.07M) | (86.39M) | (58.7M) | (65.93M) |
Precision BioSciences, Inc.
NASDAQ:DTIL
Intrinsic Alpha fair value
Locked
Current Price
$7.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.